Oakworth Capital Inc. Trims Position in Johnson & Johnson (NYSE:JNJ)

Oakworth Capital Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,331 shares of the company’s stock after selling 888 shares during the quarter. Oakworth Capital Inc.’s holdings in Johnson & Johnson were worth $2,651,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. McHugh Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $591,000. Silver Oak Securities Incorporated boosted its holdings in Johnson & Johnson by 14.8% in the fourth quarter. Silver Oak Securities Incorporated now owns 7,592 shares of the company’s stock valued at $1,088,000 after acquiring an additional 976 shares during the last quarter. Spirepoint Private Client LLC increased its stake in Johnson & Johnson by 2.8% during the fourth quarter. Spirepoint Private Client LLC now owns 97,116 shares of the company’s stock worth $14,045,000 after acquiring an additional 2,676 shares during the last quarter. Financial Advocates Investment Management raised its holdings in shares of Johnson & Johnson by 12.8% in the 4th quarter. Financial Advocates Investment Management now owns 21,029 shares of the company’s stock worth $3,041,000 after purchasing an additional 2,380 shares during the period. Finally, Adero Partners LLC lifted its stake in shares of Johnson & Johnson by 19.0% in the 4th quarter. Adero Partners LLC now owns 13,233 shares of the company’s stock valued at $1,914,000 after purchasing an additional 2,116 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on JNJ shares. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Leerink Partners decreased their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Bank of America decreased their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $153.10 on Monday. The firm has a market cap of $368.61 billion, a P/E ratio of 23.02, a P/E/G ratio of 2.46 and a beta of 0.52. The firm has a fifty day moving average of $147.42 and a two-hundred day moving average of $156.08. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.